» Articles » PMID: 21472099

Crohn's Disease: Evidence for Involvement of Unregulated Transcytosis in Disease Etio-pathogenesis

Overview
Specialty Gastroenterology
Date 2011 Apr 8
PMID 21472099
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Crohn's disease (CD) is a chronic inflammatory bowel disease. Research has identified genetic predisposition and environmental factors as key elements in the development of the disease. However, the precise mechanism that initiates immune activation remains undefined. One pathway for luminal antigenic molecules to enter the sterile lamina propria and activate an immune response is via transcytosis. Transcytosis, although tightly regulated by the cell, has the potential for transepithelial transport of bacteria and highly antigenic luminal molecules whose uncontrolled translocation into the lamina propria can be the source of immune activation. Viewed as a whole, the evidence suggests that unregulated intestinal epithelial transcytosis is involved in the inappropriate presentation of immunogenic luminal macromolecules to the intestinal lamina propria. Thus fulfilling the role of an early pre-morbid mechanism that can result in antigenic overload of the lamina propria and initiate an immune response culminating in chronic inflammation characteristic of this disease. It is the aim of this paper to present evidence implicating enterocyte transcytosis in the early etio-pathogenesis of CD.

Citing Articles

Phenolic Compounds Impact on Rheumatoid Arthritis, Inflammatory Bowel Disease and Microbiota Modulation.

Direito R, Rocha J, Sepodes B, Eduardo-Figueira M Pharmaceutics. 2021; 13(2).

PMID: 33499333 PMC: 7912052. DOI: 10.3390/pharmaceutics13020145.


Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms.

Lechuga S, Ivanov A Biochim Biophys Acta Mol Cell Res. 2017; 1864(7):1183-1194.

PMID: 28322932 PMC: 5507344. DOI: 10.1016/j.bbamcr.2017.03.007.


Mechanisms of Intestinal Epithelial Barrier Dysfunction by Adherent-Invasive .

Shawki A, McCole D Cell Mol Gastroenterol Hepatol. 2017; 3(1):41-50.

PMID: 28174756 PMC: 5247418. DOI: 10.1016/j.jcmgh.2016.10.004.


Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.

Nalle S, Turner J Mucosal Immunol. 2015; 8(4):720-30.

PMID: 25943273 DOI: 10.1038/mi.2015.40.

References
1.
Brennan P, Nikaido H . The envelope of mycobacteria. Annu Rev Biochem. 1995; 64:29-63. DOI: 10.1146/annurev.bi.64.070195.000333. View

2.
Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J . Effects of light smoking consumption on the clinical course of Crohn's disease. Inflamm Bowel Dis. 2008; 15(5):734-41. DOI: 10.1002/ibd.20828. View

3.
Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Cattan S, Gendre J . Effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment Pharmacol Ther. 1999; 13(11):1403-11. DOI: 10.1046/j.1365-2036.1999.00630.x. View

4.
Abubakar I, Myhill D, Hart A, Lake I, Harvey I, Rhodes J . A case-control study of drinking water and dairy products in Crohn's Disease--further investigation of the possible role of Mycobacterium avium paratuberculosis. Am J Epidemiol. 2007; 165(7):776-83. DOI: 10.1093/aje/kwk067. View

5.
Ehrenpreis E, Kane S, Cohen L, Cohen R, Hanauer S . Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999; 117(6):1271-7. DOI: 10.1016/s0016-5085(99)70276-3. View